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Background
Cryopyrin associated periodic syndromes (CAPS) com-
prise a spectrum of autoinflammatory disorders of vary-
ing severity caused by mutations in the NLRP3 gene.
The Q703K allele, reaching 5% of the total allele count
in the general population, is considered either functional
polymorphism or a low penetrance mutation
Aim
To describe the clinical phenotype of the Israeli patients
in whom the Q703K allele was found.
Methods
Ten patients carrying the Q703K mutation were identi-
fied among 70 patients in whom the diagnosis of CAPS
was suspected on clinical grounds.
Results
Seven female and 3 male patients with a mean age of
22.5±17.8 years and a mean diagnosis delay of 12.4
years were identified. Their clinical characteristics ran-
ged from self resolving attacks of fever, urticaria and
arthralgia to a chronic, debilitating steroid-dependent
inflammatory disease. Splenomegaly, transfusion-depen-
dent anemia, sensory neuropathy and pericarditis, mani-
festations which are not included in the traditional
CAPS-spectrum, were detected in some of the patients.
The majority of patients responded to high dose steroid
therapy. DMARDS such as methotrexate, azathioprine
and colchicine were generally ineffective at reducing
steroid dose or attack rate. Therapy with TNF inhibitors
or anti IL-1 agents was instituted in 4 patients with a
favorable response. All but one patient needed chronic
anti-inflammatory therapy to prevent attacks and reduce
steroid dose.
Conclusions
Our cohort of patients with the Q703K mutation, the
largest reported to date, show a heterogeneous inflam-
matory phenotype, in which a CAPS component may be
appreciated. Both IL-1 and TNF inhibitors seem to be
effective in treating steroid resistant manifestations of
this subgroup of CAPS patients.
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